Assessing surrogacy from the joint modelling of multivariate longitudinal data and survival: Application to clinical trial data on chronic lymphocytic leukaemia
- 3 December 2007
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 26 (30) , 5411-5421
Abstract
In clinical research, we are often interested in assessing how a biomarker changes with time, and whether it could be used as a surrogate marker when evaluating the efficacy of a new drug. However, when the longitudinal marker is correlated with survival, linear mixed models for longitudinal data may be inappropriate. By contrast, it may be possible to recover information from the so‐called informative censoring by modelling both the longitudinal information and the survival process. The objective of this work is to jointly model longitudinal and survival data to assess surrogacy. Two competitive modelling strategies were used, either a multistate model summarizing the course of longitudinal data and occurrence of disease progression or death, or a joint longitudinal‐survival model. We present both analyses based on a case study from two randomized clinical trials that enrolled patients with stage A chronic lymphocytic leukaemia (CLL) in order to obtain further insights into these different approaches. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 17 references indexed in Scilit:
- Tutorial in biostatistics: competing risks and multi‐state modelsStatistics in Medicine, 2006
- The Evaluation of Surrogate Endpoints2005
- Statistical evaluation of biomarkers as surrogate endpoints: a literature reviewStatistics in Medicine, 2005
- Joint models for efficient estimation in proportional hazards regression modelsStatistics in Medicine, 2003
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Joint modelling of longitudinal measurements and event time dataBiostatistics, 2000
- Multiple Events per Subject2000
- ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKERStatistics in Medicine, 1997
- Therapeutic Results from the Trials Managed by the French Cooperative Group on Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 1991
- On the regression analysis of multivariate failure time dataBiometrika, 1981